Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
BridgeBio Pharma Inc (NASDAQ: BBIO) closed the day trading at $33.26 down -6.78% from the previous closing price of $35.68. In other words, the price has decreased by -$6.78 from its previous closing price. On the day, 6.37 million shares were traded.
Ratios:
For a better understanding of BBIO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.54 and its Current Ratio is at 4.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on March 31, 2025, initiated with a Buy rating and assigned the stock a target price of $50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 12 ’25 when KKR Genetic Disorder L.P. bought 6,000,000 shares for $35.68 per share.
Apuli Maricel sold 1,026 shares of BBIO for $39,509 on May 02 ’25. The Chief Accounting Officer now owns 147,639 shares after completing the transaction at $38.51 per share. On May 02 ’25, another insider, Lo Andrew, who serves as the Director of the company, sold 100,000 shares for $38.50 each. As a result, the insider received 3,849,900 and left with 105,583 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 49.56.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $39.54, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is -3.27%, while the 200-Day Moving Average is calculated to be 12.34%.
Shares Statistics:
A total of 189.83M shares are outstanding, with a floating share count of 155.35M. Insiders hold about 18.18% of the company’s shares, while institutions hold 78.63% stake in the company.
